Biopsy Devices Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 3.69 billion by 2030 and is anticipated to register a CAGR of 6.1%. The biopsy is used to perform surgical removal of tissue from an organ to determine the extent of disease, generally inflammatory and cancerous conditions. They perform by radiologists, interventional cardiologists, and surgeons. Each biopsy device is used according to the types of the organ under consideration. Conventional biopsy devices are complemented with advanced imaging technologies, like a stereotactic-guided biopsy, MRI-guided biopsy, CT scans, ultrasound-guided biopsy, and others to perform a biopsy with minimal invasiveness. Equipment like forceps, aspiration needles and localization wires are commonly used in biopsy devices. These devices are used in the needle-based, core, and vacuum-assisted biopsies of body parts, including the lungs, breast, liver, and kidney. They have various applications in healthcare such as diagnostic centers, medical clinics, and hospitals.
The report " Global Biopsy Devices Market, By Device Type (Breast biopsy devices, Gastrointestinal (GI) biopsy devices, Soft tissue biopsy devices, Bronchial biopsy devices, Gynecological biopsy devices, Robotic biopsy devices, and Other devices), By Imaging Technology (CT scan, Stereotactic-guided biopsy, Ultrasound-guided biopsy, MRI-guided biopsy, and Others), By Application (Breast biopsy, Gastrointestinal (GI) biopsy, Prostate, Liver, Lung, Kidney, Gynecological, and Others), By End-User (Diagnostics and Hospitals), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030”
Key Highlights:
· On 16 March 2021, IZI Medical Products, LLC leading manufacturer of medical devices for radiology and oncology procedures, launched fully automated Quick-Core Auto Biopsy System for soft tissue biopsy. The Quick-Core Auto is a fully automatic biopsy device and lightweight, that builds upon the legacy of IZI's Quick-Core semi-automatic biopsy system, and offers the same reliability, precision, and quality.
· Hologic announced enhancement in Brevera with CorLumina Imaging Technology in August 2020. Which integrates vacuum-assisted tissue acquisition, real-time imaging verification, and advanced post-biopsy handling, the innovation will fuel the customer base of the firm.
· On 24 February 2021, Twist Bioscience Launched Industry-Leading NGS Methylation Detection System for Liquid Biopsy Cancer Analysis and Epigenetic Studies. Company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and a robust, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome.
Analyst View:
The increasing instance of chronic medical ailments, mainly breast cancer, is the key factor driving the growth of the market. In addition, increasing consumer awareness regarding the availability of screening procedures and diagnostics for chronic disease is rising the demand for integral technologies such as stereotactic-guided biopsies. Growing preference for minimally invasive (MI) biopsy procedures among patients across the globe is increasing the growth of the biopsy device market, For instance, the MI breast biopsy technique (MIBT) eliminates the need for surgery of cancer diagnosis while preserving the healthy tissue from damage caused by radiation. Furthermore, technological advancements include the development of vacuum-assisted guns and smart biopsy system that aid in distinguishing healthy cells from tumorous ones which also supports the growth of the market. The rapidly growing geriatric population, extensive research, and development activities increasing healthcare expenditure are driving the market in the coming years.
To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-Biopsy-Devices-Market-By-2809
Key Market Insights from the report:
Global Biopsy Devices Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 3.69 billion by 2030 and is anticipated to register a CAGR of 6.1%. The Global Biopsy Devices Market is segmented by Device Type, Application, Imaging Technology, End-user, and Region.
· By Device type, Global Biopsy Devices Market is segmented into Breast biopsy devices, Gastrointestinal (GI) biopsy devices, Soft tissue biopsy devices, Bronchial biopsy devices, Gynecological biopsy devices, Robotic biopsy devices, and other devices.
· By Application, Global Biopsy Devices Market is segmented into Breast biopsy, Gastrointestinal (GI) biopsy, Prostate, Liver, Lung, Kidney, Gynecological, and Others.
· By imaging technology, Global Biopsy Devices Market is segmented into CT scan, Stereotactic-guided biopsy, Ultrasound-guided biopsy, MRI-guided biopsy, and others.
· By End user, Global Biopsy Devices Market is segmented into Diagnostics and Hospitals.
Competitive Landscape:
· The key operators of the Global Biopsy Devices Market are Bard Inc., Leica Biosystems, Dickinson and Company, Ethicon EndoSurgery Inc., Fujifilm Medical Systems, Veran Medical Technologies, Boston Scientific Corporation, MDxHealth, Medtronic, Argon Medical Devices Inc.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
